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Background: The p73 protein, a paralogue of the p53 tumor suppressor, is essential for normal
development and survival of neurons. TP73  is therefore of interest as a candidate gene for
Alzheimer's disease (AD) susceptibility. TP73 mRNA is transcribed from three promoters, termed
P1 – P3, and there is evidence for an additional complexity in its regulation, namely, a variable allelic
expression bias in some human tissues.
Methods: We utilized RT-PCR/RFLP and direct cDNA sequencing to measure allele-specific
expression of TP73 mRNA, SNP genotyping to assess genetic associations with AD, and promoter-
reporter assays to assess allele-specific TP73 promoter activity.
Results: Using a coding-neutral BanI polymorphism in TP73 exon 5 as an allelic marker, we found
a pronounced allelic expression bias in one adult brain hippocampus, while 3 other brains (two
adult; one fetal) showed approximately equal expression from both alleles. In a tri-ethnic elderly
population of African-Americans, Caribbean Hispanics and Caucasians, a G/A single nucleotide
polymorphism (SNP) at -386 in the TP73 P3 promoter was weakly but significantly associated with
AD (crude O.R. for AD given any -386G allele 1.7; C.I. 1.2–2.5; after adjusting for age and education
O.R. 1.5; C.I. 1.1–2.3, N= 1191). The frequency of the -386G allele varied by ethnicity and was
highest in African-Americans and lowest in Caucasians. No significant differences in basal P3
promoter activity were detected comparing -386G vs. -386A promoter-luciferase constructs in
human SK-NSH-N neuroblastoma cells.
Conclusions: There is a reproducible allelic expression bias in mRNA expression from the TP73
gene in some, though not all, adult human brains, and inter-individual variation in regulatory
sequences of the TP73 locus may affect susceptibility to AD. However, additional studies will be
necessary to exclude genetic admixture as an alternative explanation for the observed associations.
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Background
Genes functioning in neurons could modulate AD suscep-
tibility either by acting during development to determine
the number of cortical neurons at birth, thereby determin-
ing "cognitive reserve", or by acting during adult life to
determine the cell death threshold of neurons when faced
by external insults, such as amyloid-beta peptide. In prin-
ciple, the protein encoded by TP73 could play a role in
both processes. This protein is related to p53, which trig-
gers apoptotic cell death as an effector mechanism in
tumor surveillance. p73  knockout (KO) mice are born
with disorganized hippocampal cyto-architecture, and
they show degeneration of sympathetic neurons [1,2].
Moreover, these mice, which survive to adulthood,
showed progressive cerebral atrophy [3].
Gene regulation at the TP73 locus is complex. The mRNA
transcripts are initiated from two alternative promoters,
leading to the production of two different protein iso-
forms. "Full-length" p73 mRNA, initiating from the P1
promoter, encodes a protein with an N-terminal transcrip-
tional activation domain, while the shorter "delta-N"
(∆Np73) isoform, initiating from the major downstream
P3 promoter, lacks this domain. The full-length p73 pro-
tein is pro-apoptotic, while the ∆Np73 acts as a natural
dominant-negative, and protects cells from apoptosis [4].
The fact that the ∆Np73 isoform is preferentially
expressed in neurons explains the net anti-apoptotic func-
tion of p73 in the peripheral nervous system, and proba-
bly in cortical neurons of the brain.
Some evidence suggests that there may be a second kind
of complexity at the p73 locus – allelic expression bias.
Monoallelic expression of TP73 was reported in neurob-
lastoma cells in the first publication describing this gene
[5]. Monoallelic gene expression affects loci that are sub-
ject to parental imprinting, and it was initially suggested
that TP73 might be imprinted. The significance of these
observations were called into question by the finding of
lack of imprinting of this gene in studies of the p73 KO
mice [1], and the finding of biallelic expression of TP73 in
some normal human tissues. But biased allelic expression
can have other explanations in addition to imprinting,
and a number of subsequent studies have continued to
report monoallelic or biased allelic representation of TP73
mRNA, albeit in a tissue-specific pattern, and with inter-
individual variability [5-10]. Such variation suggests that
there may be functional genetic polymorphisms in regula-
tory sequence (promoters/enhancers) of this gene. Here
we assess the allele frequencies of two TP73 SNPs in a
case-control analysis of AD in a tri-ethnic elderly popula-
tion sample, and we test for an allelic expression bias at
the TP73 locus in human brains.
Methods
Participants and diagnosis
Selection of participants and diagnosis was previously
described [11], and key aspects are repeated here. Subjects
were individuals over the age of 65 residing in the Wash-
ington Heights-Inwood neighborhood of Manhattan. For
those who agreed to participate, an in-person interview
and a standardized assessment including a medical his-
tory, physical and neurological examination and neu-
ropsychological battery [12] was completed. Individuals
who qualified for initial inclusion in the community
study (n = 1401) all had at least one subsequent follow-
up evaluation. 282 (20.1%) were non-Hispanic Whites,
462 (33%) were African-American, 646 (46.1%) were
Caribbean Hispanic and 11 (0.8%) were from other eth-
nic groups. We excluded individuals with other forms of
dementia or Parkinson's disease. DNA for genotyping was
available from most of these individuals. For AD cases, the
diagnosis was established at a consensus conference of
physicians and neuropsychologists and required evidence
of cognitive deficit on the neuropsychological battery as
well as evidence of impairment in social or occupational
function. A Clinical Dementia Rating (CDR) score of 1.0
was the cut-off for the diagnosis of AD. These studies were
approved by the Columbia University Institutional
Review Board.
DNA and RNA isolation
Peripheral blood was obtained with informed consent.
DNA for genotyping was isolated from blood using the
FlexiGene™ kit (Qiagen). To prepare DNA and RNA from
frozen brain the tissue was first pulverized under liquid
nitrogen. DNA was then isolated by standard SDS/protei-
nase-K lysis and phenol/chloroform extraction; RNA was
isolated using Trizol™ reagent (Sigma) according to the
protocol provided by the manufacturer.
TP73 SNP genotyping and mutational screening
SNP locations, PCR primers and conditions, and diagnos-
tic restriction enzymes for genotyping of TP73 polymor-
phisms are in Table 1. Mutational analysis of the P3
promoter was done from 12 individuals using the same
748 bp PCR product that was used for genotyping. For
mutation analysis of the DNA-binding domain of p73,
genomic PCR products were amplified corresponding to
exons 4 through 8 (primer sequences available on
request) and subjected to direct DNA sequencing.
Analysis of TP73 allele-specific mRNA expression
Allele-specific expression of TP73 mRNA in human brains
was analyzed by reverse transcription-PCR (RT-PCR)
using primers located in exons 4 and 6; while genomic
PCR with primers flanking exon 5 served as a control
(Table 1). First strand synthesis was with SuperScript (Inv-
itrogen), using oligo dT primer. Typically, 2 µg of totalBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/14
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RNA was used in a 20 ul reaction. After digestion with
RNaseH, 1 ul of the RT product was used for PCR. Non-
radioactive PCR products (40 cycles) were directly
sequenced, and independent radiolabeling PCR reactions,
done for a total of 35 cycles in the presence of 32PdCTP,
were digested with BanI and the fragments resolved on 8%
non-denaturing polyacrylamide gels.
TP73 P3 promoter-reporter plasmids
The P3 promoter from -675 to +1 relative to the transcrip-
tional start of exon 3bis (see Fig. 1) was amplified by
genomic PCR from a -386G/A heterozygote using high-
fidelity Taq polymerase (Roche) and the primers in Table
1 (promoter construct), cloned in the TA vector (Invitro-
gen), excised with KpnI and BglII restriction enzymes, and
the fragment ligated into the pGL3 vector (Promega)
upstream of the luciferase reporter gene. SK-NSH-N neu-
roblastoma cells, maintained in DMEM with 10% fetal
calf serum, were transfected in triplicate with 0.5 micro-
grams of the promoter-LUC plasmids, plus 0.5 micro-
grams of the Renilla luciferase control plasmid. Luciferase
assays were done 30 hours post-transfection (Dual Luci-
ferase Assay System, Promega).
APOE genotyping
Subjects were genotyped for the APOE coding polymor-
phisms, using genomic PCR followed by CfoI digestion of
the PCR products and acrylamide gel electrophoresis, as
previously described [13,14].
Statistical analysis
Allele frequencies were determined by counting each
allele and by calculating sample proportions. For compar-
ison of cases and controls within and across ethnic
groups, allele frequencies were calculated for all subjects
and compared by the chi square analysis. Logistic regres-
sion was used to compute the odds ratio (O.R.) for the
association between AD and the TP73 polymorphisms.
Data were stratified by the presence or absence of an
APOE ε4 allele and by adjusting for differences in age and
education. Logistic regression analyses were conducted
separately for each ethnic group. We tested for Hardy-
Weinberg equilibrium using a chi-square analysis. Multi-
variate logistic regression was used to compute the O.R.
for the association between AD and TP73 promoter poly-
morphisms, adjusting for age, sex, and education.
Results
The locations of the TP73 SNPs analyzed in this study are
diagrammed in Figure 1. We first genotyped all AD cases
and controls for the known BanI polymorphism in exon 5
of TP73. We observed ethnic differences in allele frequen-
cies between Caucasians, Caribbean Hispanics and Afri-
can-Americans in our population sample, with the highest
frequency of the BanI+ allele in African-Americans, but
using stringent diagnostic criteria we did not find a con-
sistent association with AD (Table 2). After segregating the
subjects by APOE genotypes, we observed a weak but sig-
nificant association of the BanI +/- genotype with AD (ref-
erence genotype BanI -/-), but no allele dosage effect was
observed, i.e. the BanI+/+ genotype was not positively cor-
related with AD (Table 3).
We therefore searched for additional sequence variants in
TP73. As a screening panel, we chose genomic DNA from
12 people (24 chromosomes), including several individu-
als from each of the three ethnic groups. This analysis
would not be expected to detect rare variants, but would
detect common alleles. Sequencing of the exons encoding
the DNA binding domain of p73 did not reveal any cod-
ing variants, although the BanI SNP, which is coding-neu-
tral, was observed with a high frequency and served as a
positive control. However, we did find a common SNP in
the P3 promoter of TP73. This variant was a G→A trans-
version at position minus-386 relative to the transcrip-
tional start site of the ∆N-p73 isoform. A transcription
factor binding site database search [15]http://
www.cbil.upenn.edu/tess/ showed that this SNP
Table 1: PCR conditions and primers for analyzing TP73 SNPs
Analysis SNP Location PCR Primers (Forward; Reverse) Anneal. 
Temp.
Size (bp) Restriction 
Enzyme
Promoter construct P3 promoter (F) GCACCACTGCAGAGCCCCTCCC (R) 
AACAACAAAACCCGCGGCCCACC
60°C 675 N/A
Genotyping P3 promoter (F) AGAGCCCCTCCCTGGCTGTGCC (R) 
CGAGGATGCTGGGGAACATGC
65°C 748 SpeI
Genotyping Exon 5 (F) ACAGGGGTGCAGTTGGGAC (R) 
CTGGGAAAATGGGGGCTGGTG
60°C 403 BanI
Allelic Expression Exon 4–6 RT-PCR (F) CTTTCCAGCAGTCCAGCACGG (R) 
CGTGGTTGGGGCAGCGTTTCA
60°C 203 BanI
Control for Allelic 
Expression
Exon 5 Genomic PCR (F) TTGGGACCACTGGTCTCA (R) 
GTGGTTGGGGCAGCGTTTCA
60°C 235 BanIBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/14
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Map of the 5' TP73 exons showing the SNPs utilized in this study Figure 1
Map of the 5' TP73 exons showing the SNPs utilized in this study. The arrows represent promoter sequences and the 
rectangles exons. The region of DNA containing the -386G/A SNP is magnified in the lower panel. The SNP is underlined and 
the dotted line indicates the variant progesterone receptor binding site (AGTCCT, consensus sequence A/TGTYCT) that 
overlaps the SNP and becomes non-consensus in the G-allele.
Table 2: Genotype frequencies of the TP73 exon 5 (BanI) polymorphism in AD cases and controls
Genotype AD Cases Controls Unadjusted Odds Ratio Adjusted for age and education
BanI -/- 200 (62.6%) 380 (68.1%) 1.0 1.0
-/+ 113 (33.8%) 154 (27.6%) 1.4; 0.9–1.8 1.4; 0.9–1.9
+/+ 12 (3.6%) 24 (3.6%) 0.9; 0.4–1.9 0.7 0.3–1.4
N3 3 4 5 5 8
Table 3: Odds ratios for AD as a function of the TP73 exon 5 (BanI) polymorphism stratified by the presence or absence of APOE ε4 
alleles
Genotype APOE 4/4 APOE -/4 APOE -/-
BanI -/- 1.0 1.0 1.0
-/+ 2.5; 0.2–29.2 0.9; 0.5–1.6 1.5; 1.1–2.2*
+/+ - 0.5; 0.2–1.8 1.4; 0.5–3.6
* p = 0.02
BanI: T/C 
P1 P3
Ex5
exons 7 - 14
Ex4 Ex6
Ex3
bis Ex3 Ex2
Ex1
bis Ex1
P2
SpeI: G/A 
Ex3
bis
-386 
3/8&WR
77**$&7* **7&&7**
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converted a variant consensus progesterone receptor bind-
ing site overlapping the -386A allele to a non-consensus
sequence in the -386G allele (Fig. 1). This SNP also
overlapped with a p53 consensus binding half-site, but no
second nearby half-site was found, suggesting that p53
binding to the P3 promoter [16] is not likely to be affected
by the -386G/A SNP.
To ask whether the -386G/A SNP might be associated with
AD risk, we genotyped the series of cases and controls.
These individuals were also genotyped for coding variants
at the APOE locus, which are known modifiers of AD risk
[17,18]. The results are shown in Table 4. The -386G/A
allelic system was in Hardy-Weinberg equilibrium in the
controls, and the -386G allele was significantly associated
with AD in the group as a whole, both when the data were
analyzed as unadjusted odds ratios, and after multivariate
logistic regression analysis correcting for age and
education.
After stratifying by APOE genotype, the AD association of
the -386G TP73 allele was seen in the groups with one or
zero APOE ε4 alleles, but was not seen in the group of
APOE ε4/ε4 homozygotes (Table 5). Since homozygosity
for APOE ε4 in itself conveys a high risk of AD, this result
is not surprising.
We next asked whether allele frequencies of the -386G/A
SNP might differ by ethnicity. As shown in Table 6, there
was indeed a difference among the three ethnic groups,
with the highest frequency of the -386G allele in African-
Americans and the lowest frequency in European Cauca-
sians. Consistent with the known history of ethnic
admixture in the Caribbean, Hispanics showed an
intermediate allele frequency. When we reexamined the
AD associations stratifying by ethnicity, we found a signif-
icant association of homozygosity for the -386G allele
with AD in the Hispanics, and a similar direction of the
effect, but failure to achieve significance, in the smaller
number of African-Americans (Table 7). There were too
few Caucasians with the -386G allele to allow
conclusions.
Table 4: Genotype frequencies of the -386G/A P3 promoter polymorphism in AD cases and controls
Genotype AD Cases Controls Unadjusted Odds Ratio Adjusted for age and education
AA 122 (30%) 288 (37%) 1.0 1.0
AG 196 (48%) 380 (48%) 1.2; 0.9–1.6 1.0; 0.7–1.3
GG 87 (22%) 118 (15%) 1.7; 1.2–2.5+ 1.5; 1.1–2.3*
N 405 786
+ p < 0.002 * p < 0.01
Table 5: Odds ratios for AD as a function of the -386G/A P3 promoter polymorphism stratified by the presence or absence of APOE ε4 
alleles
-386G/A genotype APOE 4/4 APOE -/4 APOE -/-
AA 1.0 1.0 1.0
AG 0.2; 0.02–2.6 1.2; 0.6–1.9 1.2; 0.9–1.7
GG 0.8; 0.04–16.9 2.3; 1.2–4.8* 1.6; 1.0–2.4*
* p = 0.02 The APOE ε2 and ε3 alleles are designated as (-)
Table 6: Genotype frequencies of the -386G/A SNP in three ethnic groups
-386G/A genotype Caucasian African-American Hispanic
AA 103(51%) 96 (26%) 206 (34%)
AG 88(43%) 179 (49%) 301(50%)
GG 13 (6%) 92 (25%) 99(16%)
N* 204 367 606
The difference across ethnic groups is significant X2 = 52.4, p < 0.0001 * 14 subjects are excluded because of ethnicity reported as "other".BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/14
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Although multiple interpretations of these results are pos-
sible, one hypothesis is that the -386G/A SNP, or closely
linked polymorphisms, might influence AD risk via a
functional effect on ∆Np73 expression in the brain. Small
variations in the net expression of the ∆Np73 mRNA iso-
form in human brains would be hard to quantify, but
examining allele-specific expression, in which one allele
serves as an internal control for the other, is expected to be
more sensitive. We therefore screened a series of 34 brains
for heterozygosity at the TP73 exon 5 BanI polymorphism,
which would allow mRNA from the two alleles to be dis-
tinguished by RFLP and direct sequencing. Since the col-
lection of autopsy brains available to us was primarily,
though not exclusively, from Caucasians, the allele
frequency at this marker was low. Nonetheless, we found
4 brains, 1 fetal mid-gestation and 3 adult, which were
heterozygous. Two of the adult brains were affected by AD
and one was normal.
Among these 4 brains, 3 manifested approximately equal
biallelic mRNA expression of TP73 mRNA, as indicated by
comparison with genomic PCR controls, while one adult
brain (the normal brain) showed a strong allelic expres-
sion bias (Figure 2). This bias was reproducible in
multiple independent RT-PCR reactions (Fig. 2), and was
also reproduced starting from two separate RNA
preparations from this same brain. We utilized RFLP anal-
ysis since this method gives a simple read-out of the two
alleles. Heteroduplex formation can cause artifacts in this
method when the cDNA is over-amplified, so we kept the
PCR cycle number to a minimum (35 cycles). Genomic
controls were run in parallel using the same PCR condi-
tions, and these gave highly reproducible RFLP results,
which were taken as the standard for biallelic representa-
tion. Lastly, the results of direct sequencing, which is not
sensitive to heteroduplex formation, were consistent with
the RFLP results (Fig. 2). From this analysis, we conclude
that some human brains manifest an allelic bias for TP73
mRNA expression. Lastly, we established the genotype at
the -386G/A P3 SNP in the 4 brains (Table 8). The adult
brain with strongly biased expression was indeed hetero-
zygous for this marker, but heterozygosity was also found
in the fetal brain, which showed approximately equal
biallelic mRNA expression.
Lastly, we tested for major effects of the -386G/A SNP on
P3 promoter activity by transfecting promoter-luciferase
reporter plasmids into human SK-NSH-N neuroblastoma
cells. No significant difference in basal promoter activity
was seen in this assay (Fig. 3).
Discussion
TP73  was originally identified in a common region of
DNA deletion on chromosome 1p36 in neuroblastomas,
suggesting that p73 could be a tumor suppressor. But fur-
ther studies, notably a knockout mouse model, demon-
strated that p73 is in fact required for the development,
maintenance and survival of neurons. ∆Np73 is a domi-
nant isoform in brain and it has anti-apoptotic function in
neurons. This background motivated us to examine the
possibility of an association between TP73 variants and
the risk of AD. In the current study, a nucleotide polymor-
phism, -386G/A, in the P3 promoter of TP73 (the pro-
moter that drives expression of the ∆Np73 isoform)
showed a weak but statistically significant association
with AD. Moreover, we found that 1 of 4 human brains
manifested a strong allelic expression bias at the TP73
locus, consistent with the presence of functional SNPs in
the regulatory sequences of this gene.
Our brain expression data add to the findings of one prior
study, in which 3 of 4 informative fetal brains showed vir-
tually monoallelic expression of TP73 mRNA, with one
fetal brain showing equal biallelic expression [9]. While
our current results are in a broad sense consistent with
those findings, our experimental approach was different
in two respects, which make the two sets of data comple-
mentary. First, we examined adult brains; and second, we
utilized the exon 5 BanI RFLP as a marker, while the pre-
vious study utilized a different polymorphism (StyI RFLP)
in exon 2, upstream of the P3 promoter. This second dif-
ference means that we have examined TP73  mRNA
derived predominantly from the P3 promoter (the major
isoform in neural tissues), while the prior study examined
mRNA derived exclusively from the upstream P1/P2
promoters.
Explanations for an allelic expression bias include
genomic imprinting, which seems unlikely at the TP73
Table 7: Odds ratios for AD as a function of the -386G/A P3 promoter polymorphism stratified by ethnicity
-386G/A genotype African-American Hispanic White
AA 1.0 1.0 1.0
AG 1.1; 0.6–1.9 1.1; 0.8–3.1 1.6; 0.7–3.5
GG 1.6; 0.9–3.1 1.7; 1.1–2.9* 0.6; 0.1–4.8
*p < 0.05BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/14
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Allele-specific TP73 mRNA expression in human brains Figure 2
Allele-specific TP73 mRNA expression in human brains. In the BanI RFLP autoradiograms the T-allele (uncut) is indi-
cated by the thick marker line and the C-allele (cut) by the thin marker. Additional smaller fragments ran at a lower position 
and are not shown. The genomic PCR (G) is a control for equal biallelic representation. The RT-PCR in each case was 
repeated three times from independent aliquots of cDNA (C). Direct sequencing confirms the pronounced allelic expression 
bias (stronger upper band) in adult brain 110, with the genomic sequence chromatogram serving as a control for biallelic rep-
resentation. Less pronounced but reproducible biases are seen among the other brains (weaker upper band in RT-PCR prod-
ucts from brain 86).
Table 8: Genotypes of the four informative brains examined for TP73 allele-specific mRNA expression
Brain ID Region Age Status P3 -386 (SpeI) Exon5 (BanI) p73 allelic expression
19 cerebrum 18 wk normal AG TC Biallelic
110 hippocampus 62 yrs normal AG TC Strong allelic bias
86 hippocampus 83 yrs AD AA TC Biallelic
166 hippocampus 89 yrs AD AA TC Biallelic
C/T = 0.183
C1 GC 2 C 3
Brain 110
(adult hippocampus; normal)
cDNA Genomic
C1 GC 2 C 3
Brain 19
(fetal cerebrum)
C1 GC 2 C 3
Brain 166
(adult hippocampus; AD)
C1 GC 2 C 3
Brain 86
(adult hippocampus; AD)BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/14
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locus based on the negative data from mice but has not
been strictly excluded in humans, or the presence of func-
tional sequence polymorphisms in the promoters/
enhancers of this gene. The -386G/A SNP itself is one can-
didate. The adult hippocampus that showed an allelic
expression bias in our study was indeed heterozygous for
this SNP, but in the fetal cerebral cortex that we examined,
heterozygosity for this SNP evidently did not result in
biased expression. So either the -386G/A SNP is not the
critical sequence variant, or alternatively the effect of this
variant is manifested in the adult hippocampus but not in
whole fetal cerebral cortex. Our promoter-reporter assays
in SK-NSH-N neuroblastoma cells did not indicate a
strong difference in basal P3 promoter activity in compar-
ing the -386G and -386A alleles. However, this polymor-
phism affects a predicted progesterone receptor binding
site and progesterone-dependent transcriptional activity
remains to be tested.
The interpretation of the statistical association of the -
386G allele with AD risk is amenable to several interpre-
tations. Since the -386G allele is significantly more fre-
quent in African-Americans and Caribbean Hispanics
compared to Caucasians, and since we have observed an
increased rate of AD in the former two ethnic groups in
our population sample [19], the association of the -386G
allele with AD might reflect genetic admixture. That is,
this allele may associate with AD simply because it is more
frequent in the two ethnic groups that, at least in the pop-
ulation that we have studied, have a higher frequency of
AD. That the association of the -386G allele with AD
remained significant when we confined our analysis only
to the Hispanics, together with the fact that the direction
of the observed effect was the same when the analysis was
confined to African-Americans, argues against this expla-
nation. However, these observations do not completely
exclude ethnic admixture as an explanation for our find-
ings. More interesting, of course, is the possibility that
sequence variation in or near the TP73 P3 promoter may
have a direct effect on ∆Np73 expression in the brain.
Haplotype analysis is in progress to further investigate this
question.
Authors' Contributions
Authors QL, ESA, EY, MW and SLR carried out the geno-
typing, promoter-reporter assays and allelic expression
analysis. Author JPV organized and supervised the brain
dissections and tissue banking and made the neuropatho-
logical diagnoses. Author BT conceived the study of TP73
polymorphisms and brain expression and supervised the
laboratory studies, and author RPM conceived the com-
munity-based study of AD, recruited and diagnosed the
subjects, carried out the statistical analyses and obtained
grant funding for this work.
Activity of allelic variants of the TP73 P3 promoter-luciferase constructs in SK-NSH-N neuroblastoma cells Figure 3
Activity of allelic variants of the TP73 P3 promoter-luciferase constructs in SK-NSH-N neuroblastoma cells. 
Values are mean (bars) and standard deviation (vertical lines) of triplicate determinations of firefly luciferase activity, normal-
ized to Renilla luciferase. The promoter confers a strong increase in luciferase expression compared to the vector control, but 
there is no significant difference between promoter activity of the -386G and -386A alleles in this assay.
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